Jordyn Sava is an editor for Targeted Oncology.
Neoadjuvant Pembro Plus Chemo Shows EFS Benefit at 5-Years in TNBC
November 13th 2023In an interview with Targeted Oncology, Peter Schmid, FRCP, MD, PhD, discussed the implication of findings from the KEYNOTE-522 trial of the addition of pembrolizumab to neoadjuvant chemotherapy in patients with high-risk triple-negative breast cancer.
Tailoring Approaches Beyond Steroids for irAEs in Cancer Treatment
November 11th 2023For many immune-related adverse events, steroids are used as frontline treatment. However, it remains unclear if steroids allow for preservation of the antitumor immune response, resulting in the need for more options for patients with cancer.
PDS0101, PDS0301, and Bintrafusp Alfa Enhances Survival in HPV+ Cancers
November 10th 2023The combination of and investigational immune checkpoint inhibitor, immunotherapy, and antibody-drug conjugate showed improvements in overall survival in patients with a variety of human papillomavirus-positive cancers.
Durvalumab/Bevacizumab Shows Clinically Meaningful PFS Improvement in HCC
November 9th 2023The phase 3 EMERALD-1 trial has met its primary end point and continues to assess durvalumab combined with transarterial chemoembolization and bevacizumab for the secondary end point of overall survival in patients with hepatocellular carcinoma.
Domvanalimab Regimen Shows Potential in First-Line GI Cancer Treatment
November 7th 2023Irrespective of PD-L1 expression, patients treated with domvanalimab, zimberelimab, and chemotherapy in arm A1 of the phase 2 EDGE-Gastric study demonstrated promising overall response rate and 6-month progression-free survival results.
SD-101 and Checkpoint Blockade Shows Early Favorable Outcomes in UMLM
November 6th 2023Encouraging progression-free survival and ctDNA molecular response rates were seen with SD-101 delivered via pressure-enabled drug delivery plus intravenous checkpoint inhibitors in patients with metastatic uveal melanoma with liver metastases.
FDA Grants ODD to Rhenium Obisbemeda for Breast Cancer and Leptomeningeal Metastases
November 3rd 2023Rhenium obisbemeda shows potential to address the unmet need of new treatment options for patients with breast cancer and leptomeningeal metastases and will continue to be evaluated in the ReSPECT-LM program.